This post is from a suggested group
Understanding the Epilepsy Market's Restraints and Challenges
While the epilepsy diagnosis and treatment market is experiencing robust growth, it also faces significant challenges. A major restraint is the high cost of advanced treatments, such as neurostimulation devices and novel medications, which can be a financial burden for patients and healthcare systems, particularly in developing nations. The rarity of certain epilepsy types and the high rate of drug resistance (up to 40% of patients) also present a challenge, creating a substantial unmet medical need. Furthermore, social stigma in many parts of the world can prevent individuals from seeking diagnosis and adhering to treatment, which hampers market growth and negatively impacts patient outcomes.
For a complete analysis of the market's limitations, review the Epilepsy Diagnosis and Treatment Market Forecast.